Skip to content
drillr.ai
Sign up

IONS

Ionis Pharmaceuticals, Inc.

NASDAQ · Healthcare · Biotechnology · US

$58.09
−0.07%
Ask drillr

  • Sep 4, 2026, 21:20 UTC

    Ionis Pharmaceuticals and partner Novartis announced on Friday that their experimental heart drug failed in a late-stage trial.

    Source:

  • Sep 3, 2026, 20:29 UTC

    The U.S. FDA approved Ionis Pharmaceuticals' therapy for a rare brain disorder, marking the first treatment approved for this genetic condition.

    Source:

  • Aug 28, 2026, 09:23 UTC

    AstraZeneca announced on Friday that its Phase 3 clinical trial for an experimental silencer drug in ATTR-CM patients failed to show additional benefit over existing stabilizer therapy, impacting its partnership with Ionis Pharmaceuticals and the broader market.

    Source:

  • Aug 20, 2026, 11:00 UTC

    Ionis Pharmaceuticals announced that new data on TRYNGOLZA (olezarsen), its recently approved treatment for severe hypertriglyceridemia, will be presented at the European Society of Cardiology Congress 2026 in Munich.

    Source:

  • Jul 29, 2026, 13:26 UTC

    Ionis Pharmaceuticals reported its Q2 2026 financial results, posting a loss of $0.43 per share, which beat the Zacks Consensus Estimate of a loss of $0.89 per share.

    Source:

  • Jul 29, 2026, 11:05 UTC

    Ionis Pharmaceuticals announced that chief scientific officer Frank Bennett will retire effective February 2027.

    Source:

  • Jul 27, 2026, 12:00 UTC

    RA Capital and other investors are investing $175 million in Oak Hill Bio to revive an experimental Angelman syndrome drug shelved by Roche.

    Source:

  • Jul 14, 2026, 16:17 UTC

    Hagens Berman opened an investigation into Ionis Pharmaceuticals for potential securities law violations after a trial failure caused a 23% stock drop.

    Source:

  • Jul 14, 2026, 15:06 UTC

    Ionis Pharmaceuticals begins dosing the first patient in the Phase I/II ASCEND study of ION337 for Dravet syndrome.

    Source:

  • Jul 9, 2026, 12:39 UTC

    Ionis Pharmaceuticals and AstraZeneca's phase 3 clinical trial for a heart disease treatment failed to show efficacy in preventing cardiac-related problems in patients with a rare and potentially fatal heart condition.

    Source:

  • Jul 9, 2026, 11:42 UTC

    AstraZeneca and Ionis Pharmaceuticals launched eplontersen sodium injection (Wainua) in China on July 8, 2026.

    Source:

  • Jul 6, 2026, 11:00 UTC

    Ionis Pharmaceuticals completed enrollment in the pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen for Angelman syndrome.

    Source:

  • Jun 25, 2026, 06:59 UTC

    Ionis Pharmaceuticals entered into a license agreement with Recordati for exclusive rights to develop and commercialize zilganersen for Alexander disease outside the U.S.

    Source:

  • Jun 24, 2026, 18:37 UTC

    The U.S. Food and Drug Administration approved TRYNGOLZA (olezarsen) developed by Ionis Pharmaceuticals as a treatment for severe hypertriglyceridemia.

    Source:

  • Jun 8, 2026, 00:00 UTC

    Ionis Pharmaceuticals appointed Ludwig N. Hantson and Peter N. Reikes as members of its Board of Directors, effective June 4, 2026.